The chemoenzymatic continuous-flow synthesis of captopril

Flow reactor technology represents one of the new strategies introduced to advance the sustainability of organic synthesis and shows many advantages compared to the batch methods (e.g. , increased safety, high control of reaction parameters, reduced manual handling, in-line purifications, reaction telescoping). For these reasons, continuous-flow synthesis is receiving increasing attention also in the pharmaceutical industry and, as a result, in the last years many new flow-based routes have been designed towards commercially available APIs